Primary Efficacy: Ulcer Prevention
Tegoprazan 25 mg successfully prevents NSAID-induced gastroduodenal ulcers over 24 weeks, proving statistically non-inferior to the established standard.
A Phase III Randomized Double-Blind Trial Comparing P-CAB vs PPI for Long-Term NSAID Users
Tegoprazan 25 mg successfully prevents NSAID-induced gastroduodenal ulcers over 24 weeks, proving statistically non-inferior to the established standard.
At Week 12, the heartburn-free rate was significantly higher in patients taking tegoprazan compared to those on the established standard.
Safety outcomes—including both general Adverse Drug Reactions (ADRs) and Serious Adverse Events (SAEs)—demonstrated no significant differences between treatment arms.
Tegoprazan 25 mg offers an excellent, clinically effective alternative gastroprotective therapy. Physicians can confidently prescribe this novel P-CAB to prevent peptic ulcers in patients requiring long-term NSAID treatment, with the added benefit of improved heartburn control.